Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Agendia Bv
Agendia's MammaPrint Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
January 2nd, 2009
Agendia, a world leader in molecular cancer diagnostics, today announced MammaPrint(R)'s ability to predict response to neoadjuvant chemotherapy in breast cancer. Dr. Laura van 't Veer, from the Netherlands Cancer Institute, presented the data at the 2008 San Antonio Breast Cancer Symposium (SABCS) during the session Molecular profiling for guiding therapeutic decisions. The study analyzed the association between the pathological complete response (pCR) rate and the results of the MammaPrint test. "Physicians are increasingly supportive of MammaPrint in clinical practice because they believe it provides them...
Source: Health Business Week (2009-01-02)
|
